American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma

Dennis P. O'Malley, Ahmet Dogan, Yuri Fedoriw, L. Jeffrey Medeiros, Chi Young Ok, Mohamed Salama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. In the case of overexpression of B lineage markers by Hodgkin/Reed-Sternberg cells, or a differential diagnosis that includes large B-cell lymphoma or variants, additional markers recommended are: CD45, OCT2, BOB1, CD79a and MUM1/IRF4. If primary mediastinal large B cell lymphoma is considered in the differential diagnosis, suggested additional markers include: P63, CD23, CD45 and CD79a. When considering a differential diagnosis that includes anaplastic large cell lymphoma we suggest: ALK, CD45, pan T cell antigens (such as CD2, CD5, CD7, and CD43), and cytotoxic markers (granzyme, perforin, and TIA1). If peripheral T cell lymphoma or T cell lymphomas of follicular helper origin are considered in the differential diagnosis, the following panel is recommended: pan T cell antigens, CD4, CD8, one or more follicular dendritic cell markers, and assessment for Epstein-Barr virus (EBV) infection, preferably EBV encoded RNA (EBER) as assessed by in situ hybridization When the differential diagnosis includes nodular lymphocyte predominant Hodgkin lymphoma, recommended additional studies include OCT2, CD21 and/or CD23, PD1, and assessment for EBV infection. The authors recognize that these panels may not be adequate to completely characterize other lymphomas, but these panels will usually be sufficient to distinguish classic Hodgkin lymphoma from other lymphoma types.

Original languageEnglish (US)
Pages (from-to)105-110
Number of pages6
JournalAnnals of Diagnostic Pathology
Volume39
DOIs
StatePublished - Apr 1 2019

Fingerprint

Expert Testimony
Hodgkin Disease
Registries
Differential Diagnosis
Pathology
Epstein-Barr Virus Infections
Viral Tumor Antigens
B-Cell Lymphoma
Lymphoma
Follicular Dendritic Cells
Reed-Sternberg Cells
Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
T-Lymphocytes
Granzymes
Perforin
T-Cell Lymphoma
Standard of Care
Human Herpesvirus 4
In Situ Hybridization

Keywords

  • Anaplastic large cell lymphoma
  • Angioimmunoblastic T cell lymphoma
  • CD15
  • CD30
  • Classic Hodgkin lymphoma
  • Differential diagnosis
  • Diffuse large B cell lymphoma
  • Gray zone lymphoma
  • Immunohistochemistry
  • Nodular lymphocyte predominant Hodgkin lymphoma
  • PAX5
  • Peripheral T cell lymphoma
  • Primary mediastinal large B cell lymphoma
  • T cell/histiocyte rich large B cell lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

American Registry of Pathology Expert Opinions : Immunohistochemical evaluation of classic Hodgkin lymphoma. / O'Malley, Dennis P.; Dogan, Ahmet; Fedoriw, Yuri; Medeiros, L. Jeffrey; Ok, Chi Young; Salama, Mohamed.

In: Annals of Diagnostic Pathology, Vol. 39, 01.04.2019, p. 105-110.

Research output: Contribution to journalArticle

O'Malley, Dennis P. ; Dogan, Ahmet ; Fedoriw, Yuri ; Medeiros, L. Jeffrey ; Ok, Chi Young ; Salama, Mohamed. / American Registry of Pathology Expert Opinions : Immunohistochemical evaluation of classic Hodgkin lymphoma. In: Annals of Diagnostic Pathology. 2019 ; Vol. 39. pp. 105-110.
@article{eaa4dd9d2edf4c61b561e868a8ced7fd,
title = "American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma",
abstract = "The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. In the case of overexpression of B lineage markers by Hodgkin/Reed-Sternberg cells, or a differential diagnosis that includes large B-cell lymphoma or variants, additional markers recommended are: CD45, OCT2, BOB1, CD79a and MUM1/IRF4. If primary mediastinal large B cell lymphoma is considered in the differential diagnosis, suggested additional markers include: P63, CD23, CD45 and CD79a. When considering a differential diagnosis that includes anaplastic large cell lymphoma we suggest: ALK, CD45, pan T cell antigens (such as CD2, CD5, CD7, and CD43), and cytotoxic markers (granzyme, perforin, and TIA1). If peripheral T cell lymphoma or T cell lymphomas of follicular helper origin are considered in the differential diagnosis, the following panel is recommended: pan T cell antigens, CD4, CD8, one or more follicular dendritic cell markers, and assessment for Epstein-Barr virus (EBV) infection, preferably EBV encoded RNA (EBER) as assessed by in situ hybridization When the differential diagnosis includes nodular lymphocyte predominant Hodgkin lymphoma, recommended additional studies include OCT2, CD21 and/or CD23, PD1, and assessment for EBV infection. The authors recognize that these panels may not be adequate to completely characterize other lymphomas, but these panels will usually be sufficient to distinguish classic Hodgkin lymphoma from other lymphoma types.",
keywords = "Anaplastic large cell lymphoma, Angioimmunoblastic T cell lymphoma, CD15, CD30, Classic Hodgkin lymphoma, Differential diagnosis, Diffuse large B cell lymphoma, Gray zone lymphoma, Immunohistochemistry, Nodular lymphocyte predominant Hodgkin lymphoma, PAX5, Peripheral T cell lymphoma, Primary mediastinal large B cell lymphoma, T cell/histiocyte rich large B cell lymphoma",
author = "O'Malley, {Dennis P.} and Ahmet Dogan and Yuri Fedoriw and Medeiros, {L. Jeffrey} and Ok, {Chi Young} and Mohamed Salama",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.anndiagpath.2019.02.001",
language = "English (US)",
volume = "39",
pages = "105--110",
journal = "Annals of Diagnostic Pathology",
issn = "1092-9134",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - American Registry of Pathology Expert Opinions

T2 - Immunohistochemical evaluation of classic Hodgkin lymphoma

AU - O'Malley, Dennis P.

AU - Dogan, Ahmet

AU - Fedoriw, Yuri

AU - Medeiros, L. Jeffrey

AU - Ok, Chi Young

AU - Salama, Mohamed

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. In the case of overexpression of B lineage markers by Hodgkin/Reed-Sternberg cells, or a differential diagnosis that includes large B-cell lymphoma or variants, additional markers recommended are: CD45, OCT2, BOB1, CD79a and MUM1/IRF4. If primary mediastinal large B cell lymphoma is considered in the differential diagnosis, suggested additional markers include: P63, CD23, CD45 and CD79a. When considering a differential diagnosis that includes anaplastic large cell lymphoma we suggest: ALK, CD45, pan T cell antigens (such as CD2, CD5, CD7, and CD43), and cytotoxic markers (granzyme, perforin, and TIA1). If peripheral T cell lymphoma or T cell lymphomas of follicular helper origin are considered in the differential diagnosis, the following panel is recommended: pan T cell antigens, CD4, CD8, one or more follicular dendritic cell markers, and assessment for Epstein-Barr virus (EBV) infection, preferably EBV encoded RNA (EBER) as assessed by in situ hybridization When the differential diagnosis includes nodular lymphocyte predominant Hodgkin lymphoma, recommended additional studies include OCT2, CD21 and/or CD23, PD1, and assessment for EBV infection. The authors recognize that these panels may not be adequate to completely characterize other lymphomas, but these panels will usually be sufficient to distinguish classic Hodgkin lymphoma from other lymphoma types.

AB - The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. In the case of overexpression of B lineage markers by Hodgkin/Reed-Sternberg cells, or a differential diagnosis that includes large B-cell lymphoma or variants, additional markers recommended are: CD45, OCT2, BOB1, CD79a and MUM1/IRF4. If primary mediastinal large B cell lymphoma is considered in the differential diagnosis, suggested additional markers include: P63, CD23, CD45 and CD79a. When considering a differential diagnosis that includes anaplastic large cell lymphoma we suggest: ALK, CD45, pan T cell antigens (such as CD2, CD5, CD7, and CD43), and cytotoxic markers (granzyme, perforin, and TIA1). If peripheral T cell lymphoma or T cell lymphomas of follicular helper origin are considered in the differential diagnosis, the following panel is recommended: pan T cell antigens, CD4, CD8, one or more follicular dendritic cell markers, and assessment for Epstein-Barr virus (EBV) infection, preferably EBV encoded RNA (EBER) as assessed by in situ hybridization When the differential diagnosis includes nodular lymphocyte predominant Hodgkin lymphoma, recommended additional studies include OCT2, CD21 and/or CD23, PD1, and assessment for EBV infection. The authors recognize that these panels may not be adequate to completely characterize other lymphomas, but these panels will usually be sufficient to distinguish classic Hodgkin lymphoma from other lymphoma types.

KW - Anaplastic large cell lymphoma

KW - Angioimmunoblastic T cell lymphoma

KW - CD15

KW - CD30

KW - Classic Hodgkin lymphoma

KW - Differential diagnosis

KW - Diffuse large B cell lymphoma

KW - Gray zone lymphoma

KW - Immunohistochemistry

KW - Nodular lymphocyte predominant Hodgkin lymphoma

KW - PAX5

KW - Peripheral T cell lymphoma

KW - Primary mediastinal large B cell lymphoma

KW - T cell/histiocyte rich large B cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85061785418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061785418&partnerID=8YFLogxK

U2 - 10.1016/j.anndiagpath.2019.02.001

DO - 10.1016/j.anndiagpath.2019.02.001

M3 - Article

C2 - 30802809

AN - SCOPUS:85061785418

VL - 39

SP - 105

EP - 110

JO - Annals of Diagnostic Pathology

JF - Annals of Diagnostic Pathology

SN - 1092-9134

ER -